Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +0.49%11 6-1 Month Momentum % is -12.79% as of Sep. 12, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,380 Biotechnology companies, Vyome Holdings ranks worse than 53.7% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-12), Vyome Holdings's 6-1 Month Momentum % is -12.79%.
The industry rank for Vyome Holdings's 6-1 Month Momentum % or its related term are showing as below:
HIND's 6-1 Month Momentum % is ranked worse than 53.7% of 1380
companies
in the Biotechnology industry
Industry Median: -12.79
vs HIND: -12.79
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vyome Holdings 6-1 Month Momentum % Related Terms
HIND vs INTI, AEON, LSTA: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Vyome Holdings's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a 6-1 Month Momentum % of -12.79% as of Sep. 12, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #741 out of 1380 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Vyome Holdings' 6-1 Month Momentum % too high?
Vyome Holdings' current 6-1 Month Momentum % is -12.79%. Based on the distribution chart, Vyome Holdings ranks #741 out of 1380 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' 6-1 Month Momentum % compare to INTI and AEON?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #741 out of 1380 companies for 6-1 Month Momentum %. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current 6-1 Month Momentum % is -12.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current 6-1 Month Momentum % of -12.79%. The current 6-1 Month Momentum % is -12.79%. Vyome Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current 6-1 Month Momentum % is -12.79% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
